HomepageSGIOF • OTCMKTS
add
Shionogi
Vorige slotkoers
$Â 18,05
Jaar-range
$Â 12,21 - $Â 18,05
Beurswaarde
2,23Â bln. JPY
Gem. volume
51,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 104,67Â mld. | 6,52% |
Bedrijfskosten | 56,78Â mld. | 6,29% |
Netto inkomsten | 36,63Â mld. | 5,24% |
Netto winstmarge | 35,00 | -1,19% |
Winst per aandeel | — | — |
EBITDA | 35,30Â mld. | 2,26% |
Effectief belastingtarief | 19,33% | — |
Balans
Totale activa
Totale passiva
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 374,80Â mld. | 4,67% |
Totale activa | 1,54Â bln. | 8,36% |
Totale passiva | 172,85Â mld. | 5,17% |
Totaal aandelenvermogen | 1,36 bln. | — |
Uitstaande aandelen | 850,69 mln. | — |
Koers-boekwaardeverhouding | 0,01 | — |
Rendement op activa | 4,93% | — |
Rendement op kapitaal | 5,43% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 36,63Â mld. | 5,24% |
Operationele kasstroom | 75,87Â mld. | -13,03% |
Kasstroom uit beleggingen | 9,63Â mld. | -40,11% |
Kasstroom uit financiering | -14,04Â mld. | 57,74% |
Nettomutatie in liquide middelen | 69,22Â mld. | -5,58% |
Vrije kasstroom | 75,55Â mld. | -7,61% |
Over
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Opgericht
1878
Hoofdvestiging
Website
Werknemers
4.955